NEW YORK (GenomeWeb) – The American Medical Association's CPT Editorial Panel will be discussing revisions to a number of molecular pathology codes at its February meeting, including codes describing testing for BRCA1 and BRCA2 genes.

The panel's decisions, which will be made public after the meeting, will provide guidance regarding the codes diagnostic companies can submit to payors for test billing, which in turn, has revenue implications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.